A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ELAN SEC filings page.
Elanco Animal Health Incorporated (ELAN) reported $5.1B in revenue over the twelve months to Sep 30, 2026, up 12.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Elanco's sales recovery preserved product-level margins, but rising overhead and reinvestment kept accounting profits and free cash flow uneven.
Although FY2025 produced a net loss of$232M , operating cash flow reached$560M , showing that reported earnings were pulled down by items outside ongoing cash operations. That cash did not become free cash: free cash flow fell to$284M as capital expenditures rose to$276M , so operating cash was directed toward reinvestment.
Revenue reached
Long-term debt fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Elanco Animal Health Incorporated's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Elanco Animal Health Incorporated scores 23/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Elanco Animal Health Incorporated scores 42/100 on it among other operating companies.
Elanco Animal Health Incorporated carried $0.60 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 0.60. With no EBITDA figure for fiscal year 2025, Elanco Animal Health Incorporated is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 48/100 among other operating companies measured the same way.
Elanco Animal Health Incorporated held $2.17 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 2.17. Liquidity ranks operating companies on that ratio, and Elanco Animal Health Incorporated scores 63/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Elanco Animal Health Incorporated scores 52/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Elanco Animal Health Incorporated scores 24/100 on it among other operating companies.
Elanco Animal Health Incorporated passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Elanco Animal Health Incorporated reported a net loss of $232.0M while generating $560.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Elanco Animal Health Incorporated generated $1.3B in revenue in Q3 2026. This represents an increase of 11.3% from the same quarter a year earlier. Against the prior quarter it is down 7.5%.
Elanco Animal Health Incorporated reported $18.0M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 66.7%.
Elanco Animal Health Incorporated earned $0.04 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 63.6%.
Not reported for Q3 2026.
Cash & Balance Sheet
Elanco Animal Health Incorporated generated $156.0M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 22.8% from the same quarter a year earlier. Against the prior quarter it is down 36.1%.
Elanco Animal Health Incorporated held $465.0M in cash against $3.6B in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Elanco Animal Health Incorporated's gross margin was 56.9% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.4 percentage points.
Elanco Animal Health Incorporated's net profit margin was 1.4% in Q3 2026, showing the share of revenue converted to profit. This is up 4.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.5 percentage points.
Elanco Animal Health Incorporated's quarterly ROE was 0.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.
Not reported for Q3 2026.
Capital Allocation
Elanco Animal Health Incorporated invested $99.0M in research and development in Q3 2026. This represents an increase of 11.2% from the same quarter a year earlier. Against the prior quarter it is up 7.6%.
Elanco Animal Health Incorporated invested $60.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 34.8% from the same quarter a year earlier. Against the prior quarter it is up 81.8%.
Not reported for Q3 2026.
ELAN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B+11.3% | $1.4B+10.2% | $1.4B+14.9% | $1.1B+12.2% | $1.1B+10.4% | $1.2B+4.8% | $1.2B-1.0% | $1.0B-1.4% |
| Cost of Revenue | $545.0M+2.8% | $570.0M+8.0% | $586.0M+15.1% | $555.0M+10.8% | $530.0M+7.7% | $528.0M+6.7% | $509.0M-1.2% | $501.0M-2.9% |
| Gross Profit | $720.0M+18.6% | $798.0M+11.9% | $785.0M+14.8% | $589.0M+13.5% | $607.0M+12.8% | $713.0M+3.5% | $684.0M-0.9% | $519.0M0.0% |
| R&D Expenses | $99.0M+11.2% | $92.0M0.0% | $97.0M+3.2% | $93.0M+14.8% | $89.0M+2.3% | $92.0M+3.4% | $94.0M+8.0% | $81.0M+2.5% |
| SG&A Expenses | $393.0M+12.0% | $449.0M+12.3% | $381.0M+11.7% | $338.0M+12.7% | $351.0M+8.7% | $400.0M+13.0% | $341.0M+1.2% | $300.0M+2.7% |
| Interest Expense | $59.0M+13.5% | $59.0M+22.9% | $57.0M+42.5% | $80.0M+73.9% | $52.0M-10.3% | $48.0M-26.2% | $40.0M-39.4% | $46.0M-31.3% |
| Income Tax | $6.0Mn/m | $2.0M-85.7% | $30.0Mn/m | $17.0Mn/m | -$16.0M-108.2% | $14.0M-22.2% | -$7.0Mn/m | -$43.0M-407.1% |
| Net Income | $18.0Mn/m | $54.0M+390.9% | $57.0M-14.9% | -$276.0Mn/m | -$34.0M-109.3% | $11.0Mn/m | $67.0M+109.4% | -$8.0Mn/m |
| EPS (Basic) | $0.04n/m | $0.11+450.0% | $0.11-21.4% | -$0.56n/m | -$0.07-109.5% | $0.02n/m | $0.14+133.3% | -$0.02n/m |
| EPS (Diluted) | $0.04n/m | $0.11+450.0% | $0.11-15.4% | -$0.56n/m | -$0.07-109.6% | $0.02n/m | $0.13+116.7% | -$0.02n/m |
| Diluted Shares (Avg) | 507M+2.0% | 506M+1.2% | 506M+1.4% | N/A | 497M-0.2% | 500M+1.2% | 499M+0.6% | N/A |
Not reported in any period shown, so not listed: Operating Income, EBITDA.
ELAN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $13.3B-1.6% | $13.6B-1.3% | $13.2B+2.2% | $13.4B+5.9% | $13.6B+2.0% | $13.7B-0.2% | $12.9B-7.7% | $12.6B-12.2% |
| Current Assets | $3.7B+6.7% | $3.8B+5.1% | $3.6B+4.2% | $3.5B+7.6% | $3.5B+3.8% | $3.6B-9.9% | $3.4B-15.1% | $3.2B-5.6% |
| Cash & Equivalents | $465.0M-7.9% | $530.0M-1.7% | $428.0M-12.1% | $545.0M+16.5% | $505.0M+3.1% | $539.0M+29.6% | $487.0M+41.2% | $468.0M+33.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $1.8B+6.4% | $1.8B+5.9% | $1.7B+7.9% | $1.7B+10.4% | $1.7B+4.7% | $1.7B+3.7% | $1.6B-2.8% | $1.6B-9.3% |
| Accounts Receivable | $992.0M+11.0% | $1.1B+8.9% | $1.1B+11.8% | $873.0M+8.4% | $894.0M+6.4% | $989.0M-1.0% | $970.0M-1.8% | $805.0M-4.4% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $4.8B+0.7% | $4.8B+1.8% | $4.7B+4.8% | $4.8B+8.3% | $4.8B+3.0% | $4.8B+6.2% | $4.5B+0.7% | $4.4B-13.3% |
| Total Liabilities | $6.7B-1.3% | $7.0B+0.1% | $6.7B+2.0% | $6.8B+4.5% | $6.8B+0.6% | $7.0B-10.9% | $6.6B-17.3% | $6.5B-19.9% |
| Current Liabilities | $1.8B+22.8% | $1.9B+33.0% | $1.7B+31.0% | $1.6B+21.4% | $1.5B+10.1% | $1.4B+1.6% | $1.3B+3.0% | $1.3B+6.0% |
| Non-Current Liabilities | $4.9B-7.9% | $5.1B-8.1% | $5.1B-4.9% | $5.2B+0.2% | $5.3B-1.7% | $5.6B-13.6% | $5.3B-21.0% | $5.2B-24.6% |
| Long-Term Debt | $3.6B-8.3% | $3.8B-7.3% | $3.9B-10.0% | $3.9B-7.8% | $4.0B-8.1% | $4.1B-24.1% | $4.4B-24.0% | $4.3B-25.4% |
| Total Equity | $6.6B-1.8% | $6.6B-2.8% | $6.5B+2.3% | $6.5B+7.4% | $6.7B+3.5% | $6.8B+14.0% | $6.4B+4.9% | $6.1B-2.0% |
| Retained Earnings | -$2.1Bn/m | -$2.1Bn/m | -$2.1Bn/m | -$2.2Bn/m | -$1.9Bn/m | -$1.9Bn/m | -$1.9Bn/m | -$1.9Bn/m |
ELAN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $216.0M-1.4% | $277.0M+16.9% | $13.0Mn/m | $108.0M-39.0% | $219.0M+35.2% | $237.0M+18.5% | -$4.0M-300.0% | $177.0M+12.7% |
| Depreciation & Amortization | $177.0M+0.6% | $171.0M+1.2% | $172.0M+6.8% | $174.0M+6.1% | $176.0M+3.5% | $169.0M+4.3% | $161.0M-3.0% | $164.0M-4.1% |
| Stock-Based Compensation | N/A | N/A | $21.0M+40.0% | N/A | N/A | N/A | $15.0M+36.4% | N/A |
| Capital Expenditures | $60.0M-34.8% | $33.0M-42.1% | $51.0M-21.5% | $62.0M+31.9% | $92.0M+119.0% | $57.0M+67.6% | $65.0M+170.8% | $47.0M+14.6% |
| Free Cash Flow | $156.0M+22.8% | $244.0M+35.6% | -$38.0Mn/m | $46.0M-64.6% | $127.0M+5.8% | $180.0M+8.4% | -$69.0Mn/m | $130.0M+12.1% |
| Investing Cash Flow | -$62.0Mn/m | -$110.0Mn/m | -$60.0Mn/m | -$64.0Mn/m | -$101.0M-108.1% | -$56.0Mn/m | -$58.0M-256.8% | -$90.0Mn/m |
| Financing Cash Flow | -$216.0Mn/m | -$74.0Mn/m | -$65.0M-225.0% | -$18.0Mn/m | -$153.0Mn/m | -$156.0Mn/m | $52.0Mn/m | -$32.0Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ELAN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.9%+3.5pp | 58.3%+0.9pp | 57.3%-0.1pp | 51.5%+0.6pp | 53.4%+1.2pp | 57.5%-0.7pp | 57.3%+0.1pp | 50.9%+0.7pp |
| Net Margin | 1.4%+4.4pp | 4.0%+3.1pp | 4.2%-1.5pp | -24.1%-23.3pp | -3.0%-38.3pp | 0.9%+5.1pp | 5.6%+3.0pp | -0.8%+12.8pp |
| Return on Equity | 0.3%+0.8pp | 0.8%+0.7pp | 0.9%-0.2pp | -4.2%-4.1pp | -0.5%-6.1pp | 0.2%+1.0pp | 1.1%+0.5pp | -0.1%+2.1pp |
| Return on Assets | 0.1%+0.4pp | 0.4%+0.3pp | 0.4%-0.1pp | -2.1%-2.0pp | -0.3%-3.0pp | 0.1%+0.4pp | 0.5%+0.3pp | -0.1%+0.9pp |
| Current Ratio | 2.09-0.3x | 2.05-0.5x | 2.16-0.6x | 2.17-0.3x | 2.40-0.1x | 2.60-0.3x | 2.71-0.6x | 2.44-0.3x |
| Debt-to-Equity | 0.550.0x | 0.580.0x | 0.60-0.1x | 0.60-0.1x | 0.59-0.1x | 0.61-0.3x | 0.68-0.3x | 0.70-0.2x |
| Liabilities-to-Equity | 1.010.0x | 1.060.0x | 1.030.0x | 1.040.0x | 1.010.0x | 1.03-0.3x | 1.04-0.3x | 1.07-0.2x |
| Asset Turnover | 0.090.0x | 0.100.0x | 0.100.0x | 0.090.0x | 0.080.0x | 0.090.0x | 0.090.0x | 0.080.0x |
| FCF Margin | 12.3%+1.2pp | 17.8%+3.3pp | -2.8%+3.0pp | 4.0%-8.7pp | 11.2%-0.5pp | 14.5%+0.5pp | -5.8%-3.9pp | 12.8%+1.5pp |
Not reported in any period shown, so not listed: Operating Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Elanco Animal Health Incorporated ELAN | FY2025 | $4.7B | -$232.0M | -4.9% | $12.9B | 42/100 |
| Dr. Reddy's Laboratories Limited RDY | FY2026 | $3.6B | $456.6M | 12.8% | $12.4B | 70/100 |
| Neurocrine Biosciences Inc NBIX | FY2025 | $2.9B | $478.6M | 16.7% | $15.2B | 79/100 |
| Viatris Inc. VTRS | FY2025 | $14.3B | -$3.5B | -24.6% | $22.5B | 28/100 |
| Zoetis Inc. ZTS | FY2025 | $9.5B | $2.7B | 28.2% | $32.1B | 70/100 |
| United Therapeutics Corp UTHR | FY2025 | $3.2B | $1.3B | 41.9% | $23.6B | 90/100 |
Where Elanco Animal Health Incorporated Ranks
Frequently Asked Questions
Elanco Animal Health Incorporated (ELAN) reported $4.7B in total revenue for fiscal year 2025. This represents a 6.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Elanco Animal Health Incorporated (ELAN) revenue grew by 6.2% year-over-year, from $4.4B to $4.7B in fiscal year 2025.
No, Elanco Animal Health Incorporated (ELAN) reported a net loss of $147.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $232.0M, with a net profit margin of -4.9%.
As of fiscal year 2025, Elanco Animal Health Incorporated (ELAN) had $545.0M in cash and equivalents against $3.9B in long-term debt.
Elanco Animal Health Incorporated (ELAN) had a gross margin of 55.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Elanco Animal Health Incorporated (ELAN) had a net profit margin of -4.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Elanco Animal Health Incorporated (ELAN) has a return on equity of -3.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Elanco Animal Health Incorporated (ELAN) generated $284.0M in free cash flow during fiscal year 2025. This represents a -27.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Elanco Animal Health Incorporated (ELAN) generated $560.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Elanco Animal Health Incorporated (ELAN) had $13.4B in total assets as of fiscal year 2025, including both current and long-term assets.
Elanco Animal Health Incorporated (ELAN) invested $276.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Elanco Animal Health Incorporated (ELAN) invested $368.0M in research and development during fiscal year 2025.
Elanco Animal Health Incorporated (ELAN) had a current ratio of 2.17 as of fiscal year 2025, which is generally considered healthy.
Elanco Animal Health Incorporated (ELAN) had a debt-to-equity ratio of 0.60 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Elanco Animal Health Incorporated (ELAN) had a liabilities-to-equity ratio of 1.04 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Elanco Animal Health Incorporated (ELAN) had a return on assets of -1.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Elanco Animal Health Incorporated (ELAN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $12.9B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Elanco Animal Health Incorporated (ELAN) trades at 2.5x sales, its market capitalization divided by $5.1B revenue, trailing 12 months to September 30, 2026. The market capitalization is $12.9B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Elanco Animal Health Incorporated (ELAN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Elanco Animal Health Incorporated (ELAN) reported a net loss of $232.0M while generating $560.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Elanco Animal Health Incorporated (ELAN) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.